USA flag logo/image

An Official Website of the United States Government

Company Information:

Name: METALLOPHARM, LLC
Address: 1790 Riverstone Drive
Delaware, OH
Located in HUBZone: No
Woman-Owned: No
Minority-Owned: No
URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $700,772.00 2
SBIR Phase II $2,004,496.00 1

Award List:

Novel Engineered Synthetic Metallodrugs Directed Against HCV

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Donna T. Palmer
Award Amount: $256,722.00
Abstract:
DESCRIPTION (provided by applicant): Alcohol is a high risk factor in hepatitis C virus (HCV) infection and increases the severity of the infection. It has been estimated that 35% of alcohol-dependent people carry HCV. HCV is associated with cirrhosis, liv er failure, and hepatocellular cancer, and… More

Metallodrugs Targeting HCV Protease

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: Ada S. Cowan
Award Amount: $444,050.00
Abstract:
DESCRIPTION (provided by applicant): Alcohol is a high risk factor in hepatitis C virus (HCV) infection and increases the severity of the infection. It has been estimated that 35% of alcohol-dependent people carry HCV. HCV is associated with cirrhosis, liv er failure, and hepatocellular cancer, and… More

Novel Catalytic MetalloDrug Targeting IRES RNA for Treatment of HCV Infection

Award Year / Program / Phase: 2011 / SBIR / Phase II
Agency: HHS
Principal Investigator: Ada S. Cowan – 740-815-9851
Award Amount: $2,004,496.00
Abstract:
DESCRIPTION (provided by applicant): HCV is responsible for 60% of the cases of chronic hepatitis and 50% of cases of cirrhosis, end- stage liver disease, and liver cancer. An effective vaccine has proved elusive and the preferred therapy with pegylated interferon is effective in less than 50% of… More